StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Sign in to jot down a private note about NEUP. Only you ever see it.
External sites have their own terms, paywalls, and accuracy standards. Stonvex doesn't endorse the content there.
Three bull points, three bear points, and one “what would change my mind” line — both sides forced onto one screen as a research note rather than a tip sheet.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-14 | $4.99 | $5.09 | +2.00% | 0.0M |
| 05-15 | $5.10 | $4.73 | -7.25% | 0.1M |
| 05-18 | $4.84 | $4.72 | -2.41% | 0.0M |
| 05-19 | $4.77 | $4.77 | +0.00% | 0.2M |
| 05-20 | $4.71 | $4.93 | +4.67% | 0.1M |
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Annual 2025 2025-06-30 | Q1 2025 2025-03-31 | Q4 2024 2024-12-31 |
|---|---|---|---|
Revenue | $15.65M | $15.66M | $662.72K |
Operating Income | $-1.13M | $4.71M | $-7.27M |
Net Income | $-400.00K | $8.51M | $-1.94M |
EPS (Diluted) | $-0.23 | $5.56 | $-4.59 |
Total Assets | $28.59M | $30.71M | $18.17M |
Total Liabilities | $9.59M | $4.72M | $4.42M |
Cash & Equivalents | $14.21M | $17.04M | $4.34M |
Free Cash Flow OCF − CapEx | Not available | Not available | Not available |
Shares Outstanding | 1.98M | 1.85M | 1.63M |
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.